SCHEMBL104496

SCHEMBL104496

C1#CCCCCCCC[CH]1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19180789 1.00
SCHEMBL8620007 1.00
SCHEMBL16534584 1.00
SCHEMBL9247701 1.00
SCHEMBL8617092 1.00
SCHEMBL9458959 1.00
SCHEMBL105791 1.00
SCHEMBL5575725 1.00
SCHEMBL147690 0.97
SCHEMBL246512 0.88

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 485 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240207300-A1 COMBINATION THERAPIES INCLUDING MYT1 INHIBITORS SINAI HEALTH SYSTEM (CA) 2024-06-27 US disclosed
US-20240173330-A1 USE OF ATR INHIBITORS IN COMBINATION WITH PARP INHIBITORS FOR TREATING CANCER REPARE THERAPEUTICS INC (CA) 2024-05-30 US disclosed
WO-2024104282-A1 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE 捷思英达控股有限公司 2024-05-23 WO disclosed
WO-2024093980-A1 PHOSPHATE SALT AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF 中国石油化工股份有限公司 2024-05-10 WO disclosed
EP-4355334-A1 USE OF ATR INHIBITORS IN COMBINATION WITH PARP INHIBITORS FOR TREATING CANCER Repare Therapeutics Inc. (CA) 2024-04-24 EP disclosed
WO-2024074559-A1 COMBINATION OF SUBSTITUTED 2,4 DIAMINO-QUINOLINE COMPOUNDS AND MEK INHIBITORS FOR USE IN THE TREATMENT OF LIVER CANCERS GENOSCIENCE PHARMA (FR) 2024-04-11 WO disclosed
EP-4349336-A1 COMBINATION OF SUBSTITUTED 2,4 DIAMINO-QUINOLINE COMPOUNDS AND MEK INHIBITORS FOR USE IN THE TREATMENT OF LIVER CANCERS Genoscience Pharma (FR) 2024-04-10 EP disclosed
WO-2024069592-A1 N-(5-SUBSTITUTED-[(L,3,4-THIADIAZOLYL) OR (L,3-THIAZOLYL)](SUBSTITUTED)CARBOXAMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING THE AMIDE COMPOUNDS AND OF THEIR USE REPARE THERAPEUTICS INC. (CA) 2024-04-04 WO disclosed
WO-2023159307-A9 POLO-LIKE KINASE 4 (PLK4) INHIBITORS, PHARMACEUTICAL COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF REPARE THERAPEUTICS INC. (CA) 2024-03-21 WO disclosed
EP-4330426-A1 METHODS OF TREATING CANCERS HAVING A BIALLELIC LOSS OF FUNCTION OR GENE OVEREXPRESSION MUTATION Repare Therapeutics Inc. (CA) 2024-03-06 EP disclosed
US-20020161008-A1 2,4-Substituted pyridine derivatives NEUROGEN CORPORATION 2002-10-31 US disclosed
WO-2002014269-A2 2,4-SUBSTITUTED PYRIDINE DERIVATIVES NEUROGEN CORPORATION (US) 2002-02-21 WO disclosed
EP-1173438-A1 SUBSTITUTED IMIDAZOLES, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2002-01-23 EP disclosed
WO-2000063208-A1 SUBSTITUTED IMIDAZOLES, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2000-10-26 WO disclosed
EP-0882016-B1 ALKYLATED STYRENES AS PRODRUGS TO COX-2 INHIBITORS MERCK FROSST CANADA INC (CA) 2000-05-31 EP disclosed
US-5925631-A NOVEL PRODRUGS ARE CONVERTED IN VIVO TO SELECTIVE CYCLOOXYGENASE-2 INHIBITORS; NONSTEROIDAL ANTIINFLAMMATORY AGENTS; SIDE EFFECT REDUCTION MERCK & CO., INC. (US) 1999-07-20 US disclosed
EP-0882016-A1 ALKYLATED STYRENES AS PRODRUGS TO COX-2 INHIBITORS MERCK FROSST CANADA INC. (CA) 1998-12-09 EP disclosed
US-5817853-A Preparation of acyloxyalkoxysilanes BASF AKTIENGESELLSCHAFT (DE) 1998-10-06 US disclosed
US-5789413-A ANTIINFLAMMATORY AGENT MERCK FROSST CANADA, INC. (CA) 1998-08-04 US disclosed
WO-1997028121-A1 ALKYLATED STYRENES AS PRODRUGS TO COX-2 INHIBITORS MERCK FROSST CANADA INC. (CA) 1997-08-07 WO disclosed